greeksoup/ stock research

Inhibrx Biosciences (INBX) Q3 FY2026 earnings: revenue $2 million

Inhibrx Biosciences, Inc. (INBX) reported revenue of $2 million for Q3 FY2026, the quarter ended 30 September 2026. Net income was -$39 million, and diluted earnings per share $-2.46. The figures are the company's own, from the 10-Q it filed with the SEC on 13 November 2026.

Revenue
$2 million
Q3 FY2024Q3 FY2026
Operating margin
-1586.8%
Q3 FY2024Q3 FY2026
Net income
-$39 million
Q3 FY2024Q3 FY2026
Diluted EPS
-$2.46
Q3 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 2 new.

  • Q3 net loss widened to $38.7M: Net loss was $38.7 million, or $2.46 per share, basic and diluted, against $35.3 million, or $2.28 per share, a year earlier.
  • Pfizer license added $2.0M revenue: The company recognized $2.0 million of revenue from a non-exclusive patent license with Pfizer, paid upfront in September 2026. No revenue was recognized in the third quarter of 2025.
  • Chondrosarcoma readiness advancing on timeline: Commercial readiness for ozekibart in conventional chondrosarcoma is advancing in line with the regulatory review timeline.
Read the earnings call summary

Income statement (profit and loss)

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Revenue2.00.00.0
Research and development26.023.928.5+8.6%-9.0%
Operating income-31.7-32.1-33.8
Operating margin-1586.8%n/an/a
Interest expense8.85.73.2+53.8%+175.2%
Pre-tax income-38.7-36.6-35.3
Income tax0.00.00.0
Net income-38.7-36.6-35.3
Net margin-1936.6%n/an/a
Diluted EPS-$2.46-$2.34-$2.28
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Operating cash flow-34.6-29.9-33.8
Capital expenditure0.00.00.0+190.0%
Free cash flow-34.6-29.9-33.8
Free cash flow margin-1731.7%n/an/a
Cash from investing-0.00.0-0.0
Cash from financing1011.60.4+6,181.7%+28,524.7%
Depreciation and amortisation0.50.50.6-1.7%-11.7%
Share-based compensation3.33.13.2+7.7%+5.3%
Diluted shares, weighted16m16m15m+0.3%+1.6%
Shares outstanding at period end15m15m14m+0.3%+1.8%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Shareholders' equity-85.9-53.036.8
Debt27717699.9+57.0%+176.9%
Operating lease liabilities2.22.94.7-24.1%-54.4%
Other liabilities27.328.136.0-2.7%-24.1%
Total liabilities and equity220154177+42.8%+24.1%
Fixed assets2.22.74.3-19.0%-49.5%
Cash and equivalents199133153+49.6%+30.3%
Other assets18.618.220.1+2.5%-7.1%
Total assets220154177+42.8%+24.1%

Questions

What was Inhibrx Biosciences' revenue in Q3 FY2026?

Inhibrx Biosciences (INBX) reported revenue of $2 million for Q3 FY2026, the quarter ended 30 September 2026.

How much did Inhibrx Biosciences earn in Q3 FY2026?

Net loss for Q3 FY2026 was $39 million, and the diluted loss per share $2.46.

When did Inhibrx Biosciences report Q3 FY2026 results?

Inhibrx Biosciences filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 13 November 2026.

Quarterly results, the last 12 quarters

Q2 FY2023Q3 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q2 FY2026Q3 FY2026
Revenue0.00.10.00.10.00.10.01.30.00.00.02.0
R&D34.138.163.967.638.933.436.922.328.525.323.926.0
Operating income-41.3-45.8-73.8-161-46.8-49.9-42.9-27.4-33.8-30.9-32.1-31.7
Operating margin-137797%-38510%n/a-160898%n/a-49928%n/a-2107%n/an/an/a-1587%
Interest expense7.98.18.15.40.00.02.73.13.23.25.78.8
Pre-tax income-47.0-51.8-78.71,858-43.9-47.9-43.3-28.7-35.3-32.8-36.6-38.7
Tax raten/an/an/a0%n/an/an/an/an/an/an/an/a
Net income-47.1-51.8-78.71,858-43.9-47.9-43.3-28.7-35.3-32.8-36.6-38.7
Net margin-156840%-43520%n/a1858011%n/a-47865%n/a-2204%n/an/an/a-1937%
Diluted EPS-$4.31-$4.39-$5.77$125.48-$2.84-$3.09-$2.80-$1.85-$2.28-$2.11-$2.34-$2.46
Operating cash flown/a-54.2-63.0-57.4-30.3-43.7-35.9-30.0-33.8-30.1-29.9-34.6
Capital expendituren/a0.81.11.20.20.00.00.00.00.00.00.0
Free cash flown/a-55.1-64.2-58.6-30.5-43.7-35.9-30.0-33.8-30.1-29.9-34.6
Shares outstanding14m14m14m14m14m14m14m14m14m15m15m15m
Filing10-Q10-Q10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 13 November 2026: the filing.